BLFS — BioLife Solutions Income Statement
0.000.00%
Last trade - 00:00
- $747.45m
- $738.73m
- $143.27m
- 57
- 30
- 76
- 54
2019 December 31st | R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 27.4 | 48.1 | 119 | 162 | 143 |
Cost of Revenue | |||||
Gross Profit | 18.6 | 27.4 | 37 | 53.8 | 46.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17.5 | 54.3 | 148 | 307 | 209 |
Operating Profit | 9.89 | -6.24 | -28.7 | -146 | -65.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.2 | -1.28 | -29 | -145 | -66.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.66 | 1.98 | -8.91 | -140 | -66.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.66 | 1.98 | -8.91 | -140 | -66.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.66 | 1.82 | -8.91 | -140 | -66.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.391 | 0.087 | -0.315 | -1.59 | -1.36 |